Xalkori
Generic name: Crizotinib
Drug class:
Multikinase inhibitors
Usage of Xalkori
Xalkori is a cancer medication that interferes with the growth and spread of cancer cells in the body.
Xalkori is used to treat non-small cell lung cancer that has spread to other parts of the body and is caused by a defect in either a gene called ALK (anaplastic lymphoma kinase) or a gene called ROS1.
Xalkori is used to treat anaplastic large cell lymphoma (ALCL) in young adults and children 1 year of age and older whose cancer is ALK-positive. It is used when the ALCL has returned or when a treatment has been tried and it did not work or is no longer working.
Xalkori is also used to treat ALK-positive inflammatory myofibroblastic tumors (IMT) in adults and pediatric patients 1 year of age and older. It is used when the IMT cannot be surgically removed, or has returned, or when a treatment has been tried and it did not work or is no longer working.
Xalkori may also be used for purposes not listed in this medication guide.
It is not known if Xalkori is safe and effective in older adults with ALCL or in children younger than 1 year of age with ALCL or IMT.
Xalkori side effects
Get emergency medical help if you have signs of an allergic Reaction to Xalkori: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have:
Common Xalkori side effects may include:
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before taking Xalkori
You should not use Xalkori if you are allergic to crizotinib.
To make sure Xalkori is safe for you, tell your doctor if you have:
Crizotinib can harm an unborn baby or cause birth defects if the mother or the father is using this medicine.
You may need to have a negative pregnancy test before starting this treatment.
This medicine may affect fertility (ability to have children) in both men and women. However, it is important to use birth control to prevent pregnancy because crizotinib can harm an unborn baby.
You should not breastfeed while you are taking Xalkori and for at least 45 days after your last dose.
Relate drugs
- Afatinib
- Alecensa
- Alectinib
- Alunbrig
- Avapritinib
- Ayvakit
- Cobimetinib
- Cotellic
- Crizotinib
- Balversa
- Binimetinib
- Braftovi
- Brigatinib
- Capmatinib
- Ceritinib
- Dabrafenib
- Deucravacitinib
- Encorafenib
- Entrectinib
- Erdafitinib
- Fedratinib
- Futibatinib
- Gavreto
- Gilotrif
- Gilteritinib
- Infigratinib
- Inrebic
- Jakafi
- Koselugo
- Larotrectinib
- Litfulo
- Lorbrena
- Lorlatinib
- Lytgobi
- Mekinist
- Mektovi
- Midostaurin
- Momelotinib
- Nintedanib
- Ofev
- Ojjaara
- Pacritinib
- Pemazyre
- Pemigatinib
- Pexidartinib
- Pralsetinib
- Qinlock
- Retevmo
- Ripretinib
- Ritlecitinib
- Rozlytrek
- Ruxolitinib
- Ruxolitinib (Oral)
- Rydapt
- Selpercatinib
- Selumetinib
- Sotyktu
- Tabrecta
- Tafinlar
- Tepmetko
- Tepotinib
- Trametinib
- Truseltiq
- Turalio
- Ukoniq
- Umbralisib
- Vemurafenib
- Vitrakvi
- Vonjo
- Xalkori
- Xospata
- Zelboraf
- Zykadia
How to use Xalkori
Usual Adult Dose for Non-Small Cell Lung Cancer:
250 mg orally twice a day Use: For the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test Comments: -Select patients for the treatment of metastatic NSCLC based on the presence of ALK or ROS1 positivity in tumor specimens. -Continue treatment until disease progression or uNACceptable toxicity.
Usual Pediatric Dose for Lymphoma:
280 mg/m2 orally twice a day Use: For the treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive.
Usual Adult Dose for Inflammatory Myofibroblastic Tumor:
250 mg orally twice a day
Use: For the treatment of adults with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive.
Usual Pediatric Dose for Inflammatory Myofibroblastic Tumor:
280 mg/m2 orally twice a day
Use: For the treatment of pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive.
Warnings
Xalkori can cause serious heart or liver problems. Call your doctor at once if you have: fast or pounding heartbeats, sudden dizziness, shortness of breath, tiredness, itching, upper stomach pain, dark urine, clay-colored stools, or jaundice (yellowing of the skin or eyes).
Do not use Xalkori if you are pregnant. It could harm the unborn baby. Use effective birth control while you are using this medicine and for at least 3 months after your treatment ends, whether you are a man or a woman.
Before you take Xalkori, tell your doctor if you have liver or kidney disease, a heart rhythm disorder, an electrolyte imbalance (such as low levels of potassium or magnesium in your blood), or a personal or family history of Long QT syndrome.
What other drugs will affect Xalkori
Sometimes it is not safe to use certain medications at the SAMe time. Some drugs can affect your blood levels of other drugs you take, which may increase side effects or make the medications less effective.
Crizotinib can cause a serious heart problem. Your risk may be higher if you also use certain other medicines for infections, asthma, heart problems, high blood pressure, depression, mental illness, cancer, malaria, or HIV.
Many drugs can interact with crizotinib. This includes prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed here. Tell your doctor about all your current medicines and any medicine you start or stop using.
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions